Anti-coronavirus vaccines: an updated summary A race against time, but run necessarily observing the immunobiology rules

Journal title PNEI REVIEW
Author/s Mauro Bologna
Publishing Year 2020 Issue 2020/1 Language Italian
Pages 6 P. 26-31 File size 285 KB
DOI 10.3280/PNEI2020-001003
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

The numerous ongoing research programs aimed at finding and producing rapidly an effective anti-coronavirus vaccine require some explanations about the vaccine immunobiology principles. In this article, the fundamental concepts of modern vaccine preparation are summarized and some of the main research initiatives in vaccine production are illustrated. The author hopes that positive results may emerge soon, allowing the solution of the current coronavirus pandemics emerged at the end of 2019 and still ongoing worldwide.

Keywords: Vaccines, Coronavirus, Virus nCoV-SARS-2, Pandemics, CoVid-19, Immunobiology.

  1. Bongini J. (2020). Coronavirus: the first batch of the vaccine will be manufactured in Pomezia, Rome, Italy. -- Testo disponibile al sito: https://www.irbm.com/web-review/coronavirus-prime-mille-dosi-del-vaccino-saranno-prodotte-a-pomezia/, visitato il 14/05/2020.
  2. Callaway E. (2020). The race for coronavirus vaccines: a graphical guide. Nature, 580: 576-577.
  3. Moderna (2020). Moderna’s Work on a Potential Vaccine Against COVID-19. -- Testo disponibile al sito: https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19, visitato il 14/05/2020.
  4. TrialSite News (2020). CanSino Biologics’ Ad5-nCoV the First COVID-19 Vaccine to Phase II Clinical Trials. -- Testo disponibile al sito: https://www.trialsitenews.com/cansino-biologics-ad5-ncov-the-first-covid-19-vaccine-to-phase-ii-clinical-trials/, visitato il 14/05/2020.
  5. Tricou V., Sáez-Llorens X., Yu D., Rivera L., Jimeno J., Villarreal A.C., Dato E., Saldaña de Suman O., Montenegro N., DeAntonio R., Mazara S., Vargas M., Mendoza D., Rauscher M., Brose M., Lefevre I., Tuboi S., Borkowski A., and Wallace D. (2020). Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet, 395(10234): 1434-1443. DOI: 10.1016/S0140-6736(20)30556-

Mauro Bologna, Vaccini anti coronavirus: facciamo il punto Una corsa contro il tempo, ma svolta necessariamente secondo le regole dell’immunobiologia in "PNEI REVIEW" 1/2020, pp 26-31, DOI: 10.3280/PNEI2020-001003